Pharmacists in Fort Wayne, Indiana


429 Pharmacists found in Fort Wayne
female pharmacist

Dr. Vivian Marie Kadus, PHARMD


Pharmacist
11109 Parkview Plaza Dr, Fort Wayne, IN 46845
260-266-1000    

male pharmacist

Mr. Walter Victor Maikranz, RPH


Pharmacist
6326 Salge Dr, Fort Wayne, IN 46835
260-486-2557     260-486-2557

male pharmacist

William Armstrong


Pharmacist
11109 Parkview Plaza Dr, Fort Wayne, IN 46845
260-266-4460    



male pharmacist

William Stuart Weber


Pharmacist
10230 Chestnut Plaza Dr, Fort Wayne, IN 46814
260-625-5198     260-625-5627

male pharmacist

William Stoffel, RPH


Pharmacist
6202 W Jefferson Blvd, Fort Wayne, IN 46804
260-432-5120    

female pharmacist

Youlijan Samy


Pharmacist
2121 Lake Ave, Fort Wayne, IN 46805
260-426-5431    

male pharmacist

Yousef Almani


Pharmacist
1615 Vintage Hill Cv, Fort Wayne, IN 46845
260-415-7314    

male pharmacist

Zach Crabill, PHARMD


Pharmacist
11109 Parkview Plaza Dr, Fort Wayne, IN 46845
260-266-4400    

male pharmacist

Dr. Zachary D Smith, PHARMD


Pharmacist
2410 N Coliseum Blvd, Fort Wayne, IN 46805
260-483-5612    

male pharmacist

Dr. Zachary L Roberts, PHARMD


Pharmacist
12279 Bluffton Road, Fort Wayne, IN 46809
734-343-7606    

male pharmacist

Zachary Scot Brown, PHARMD


Pharmacist
11109 Parkview Plaza Dr, Fort Wayne, IN 46845
260-266-1000    

female pharmacist

Dr. Zhixi Liu, PHARMD


Pharmacist
11109 Parkview Plaza Dr, Fort Wayne, IN 46845
260-266-1000    

female pharmacist

Zsanett Kormanyos, PHARMD


Pharmacist
11109 Parkview Plaza Dr, Fort Wayne, IN 46845
260-266-1000    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.